SPECTRUM PHARMACEUTICALS INC (SPPI)       0.4226  -0.02 (-5.03%)

0.4226  -0.02 (-5.03%)

US84763A1088 - Common Stock - After market: 0.424 +0 (+0.33%)


Fundamental Rating

2

Overall SPPI gets a fundamental rating of 2 out of 10. We evaluated SPPI against 636 industry peers in the Biotechnology industry. Both the profitability and financial health of SPPI have multiple concerns. While showing a medium growth rate, SPPI is valued expensive at the moment.




Profitability

Profitability Rating

1

SPPI has negative profitability rations, so we won't be analyzing them here.
SPPI's Return On Assets of -89.24% is worse than the rest of the industry. The industry average Return On Assets is -44.51%. 80% of the industry peers have a better Return On Assets.

SPPI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of SPPI.
VS Industry

ROA (-89.24%) VS Industry: 20% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

1

With a price book ratio of 2.40, SPPI is valued correctly.
The Price/Earnings Ratio is negative for SPPI. In the last year negative earnings were reported.

Also next year SPPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Compared to an average industry price book ratio of 1.63, SPPI is valued more expensive than its industry peers.
VS Industry

Price/Book (2.4) VS Industry: 35% outperformed.

134.19
0.09

Growth

Growth Rating

4

The Earnings Per Share has grown by an impressive 41.12% over the past year.

SPPI is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 11.06% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 41.12% 45.57% 29.57% 22.88% 11.06%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

2

SPPI has a Current Ratio of 2.28. This indicates that SPPI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.09 indicates that SPPI has no problem at all paying its short term obligations.
When comparing the Current Ratio of SPPI to the average industry Current Ratio of 6.12, SPPI is less able to pay its short term obligations than its industry peers. 83% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.04, SPPI is worse placed to pay its short term obligations than its industry peers. 82% of its industry peers have a better Quick Ratio.

Compared to an average industry Debt to Equity Ratio of 0.00, SPPI is requires more financing than its industry peers. 94% of its industry peers have a better Debt to Equity Ratio.
SPPI has an Altman-Z score of -14.49. This is a bad value and indicates that SPPI is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of SPPI to the average industry Altman-Z score of -0.65, SPPI is less financially healthy than its industry peers. 90% of its industry peers have a better Altman-Z score.
SPPI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of SPPI.
VS Industry

Debt/Equity (0.79) VS Industry: 6% outperformed.

15.37
0.00

Quick Ratio (2.09) VS Industry: 18% outperformed.

0.02
84.53

Current Ratio (2.28) VS Industry: 17% outperformed.

0.02
85.09

Altman-Z (-14.49) VS Industry: 10% outperformed.

-1,822.17
440.11

Dividend

Dividend Rating

0

SPPI does not give a dividend.

SPPI Daily chart

SPECTRUM PHARMACEUTICALS INC0.4226

NASDAQ:SPPI (12/9/2022, 7:09:57 PM)-0.02 (-5.03%)

After market: 0.424 +0 (+0.33%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-10 2022-11-10/amc Earnings (Next) 03-15 2023-03-15
Ins Owners 1.75% Inst Owners 25.99%
Market Cap 85.87M Analysts 80
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 2.4
EV/EBITDA N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP 0% Ex-Date N/A
Growth
EPS 1Y 41.12% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 42.86%
EPS Next Y 45.57% EPS Next 2Y 29.57%
EPS Next 3Y 22.88% EPS Next 5Y 11.06%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 2.28 Quick Ratio 2.09
Altman-Z -14.49 F-Score 3
Debt/Equity 0.79 WACC N/A
ROIC/WACC N/A
Profitability
ROA -89.24% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA